| P2093 | author name string | V Rohmer | |
| | J-L Sadoul | |
| | F Illouz | |
| P2860 | cites work | Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis | Q28218484 |
| | Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data | Q30666654 |
| | Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors | Q33388237 |
| | Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. | Q33484071 |
| | 90Y-edotreotide for metastatic carcinoid refractory to octreotide | Q34101554 |
| | An analysis of 8305 cases of carcinoid tumors | Q34415827 |
| | Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients | Q34729926 |
| | TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. | Q35837124 |
| | Nuclear imaging of neuroendocrine tumours | Q36768664 |
| | Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. | Q37157606 |
| | ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification | Q37342488 |
| | ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide | Q37588379 |
| | ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors | Q37588388 |
| | Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors | Q37649127 |
| | Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study | Q40292210 |
| | Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide | Q41096705 |
| | The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy | Q43059527 |
| | Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. | Q43227189 |
| | Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. | Q43260540 |
| | 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy | Q43290075 |
| | Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors | Q43690572 |
| | Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies | Q43966904 |
| | Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography | Q45310724 |
| | Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours | Q46167330 |
| | Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. | Q46560292 |
| | Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival | Q46619794 |
| | Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors | Q46975692 |
| | Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. | Q51571439 |
| | [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT]. | Q53303272 |
| | Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. | Q53343316 |
| | Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. | Q53425366 |
| | 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors | Q56988669 |
| | 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT | Q57757715 |
| | Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study | Q71112902 |
| | Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management | Q73047885 |
| | Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use | Q73697718 |
| | Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management | Q74329765 |
| | Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors | Q74784133 |
| | Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours | Q77566143 |
| | Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? | Q79923963 |
| | Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think... | Q82241569 |
| P407 | language of work or name | French | Q150 |
| P304 | page(s) | S3-12 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Annales d'Endocrinologie | Q15753551 |
| P1476 | title | Somatostatin receptor-based imaging and therapy of digestive endocrine tumors | |
| P478 | volume | 71 Suppl 1 | |